Review articles

Advances in tumour markers for diagnosis of hepatocellular carcinoma

Expand
  • Cancer Biological Diagnosis and Treatment Center, The Third Affiliated Hospital of Soochow University, Changzhou Jiangsu 213003, China; Institute of Cell Therapy, Soochow University, Jiangsu Changzhou 213003, China

Received date: 2023-11-10

  Online published: 2024-03-15

Abstract

According to the data from the Chinese Centre for Disease Control and Prevention, the liver cancer ranks second among malignant tumour deaths in China, with a high mortality rate. Liver cancer is characterized by difficult of early diagnosis (about 50% of patients missed), high malignant level, strong heterogeneity, and rapid progression. Early diagnosis can help patients seize the best chance for treatment, reduce the damage to the body, improve the treatment effect, and prolong survival. The main pathological type of liver cancer is hepatocellular carcinoma(HCC). Commonly used clinical tumour markers for HCC include α-fetoprotein (AFP), protein induced by vitamin K deficiency or antagonist-Ⅱ (PIVKA-Ⅱ), a-L-fucosidase (AFU), etc., which are simple and efficient. However, due to the heterogeneity of liver cancer, the marker levels in some patients were not abnormal, and 52% of HCC patients with small tumours (<3 cm) were AFP-negative, which affected the diagnostic accuracy of HCC. Therefore, some novel tumour markers have been discovered, including circulating tumour cells (CTCs), circulating cell-free nucleic acids [including circulating cell-free DNA (cfDNA) and microRNAs (miRNAs)], and exosomes. It revealed that 90.81% of CTC positive HCC patients (including early disease patients) can detect very small HCC nodules after 3-5 months of follow-up, indicating a high correlation between CTC and HCC characteristics. Postoperative monitoring of CTC levels can predict HCC recurrence before clinical detection of recurrent nodules; cfDNA can serve as an effective tool for early diagnosis of HCC, and detecting mutations in ctDNA can guide targeted therapy; miRNA can serve as a biomarker for diagnosing diseases and monitoring disease progression and prognosis; The joint detection of AFP and lncRNAs panel (including three circulating exosome sources of long chain non coding RNAs: ENSG00000248932.1, ENST000000440688.1, ENST000000457302.2) showed higher sensitivity and specificity than the single detection of AFP (AUC: 0.910 and 0.408), which can predict the occurrence of HCC and dynamically monitor HCC metastasis.However, these new tumour markers still have some limitations such as high false-negative rate at low levels, and limitation in stability due to the lack of standardized pre-analytical variables and analytical variables. These tumour markers are still not recommended to be used independently for early screening, monitoring or large-scale clinical application of HCC, and can only be used as a supplement to traditional diagnostic methods. This article reviewed the research progress of tumour markers in the diagnosis of HCC in recent years, summarized the efficacy of traditional tumour markers (AFP, PIVKA-Ⅱ. and AFU, etc.), introduced the research progress and clinical application of new tumour markers (CTC, cfDNA, ctDNA, miRNA and exosomes, etc.), and looked forward to improving the accuracy of HCC diagnosis in the future.

Cite this article

DAI Jingyi, JIANG Jingting . Advances in tumour markers for diagnosis of hepatocellular carcinoma[J]. Journal of Diagnostics Concepts & Practice, 2023 , 22(05) : 486 -493 . DOI: 10.16150/j.1671-2870.2023.05.011

References

[1] SIEGEL R L, GIAQUINTO A N, JEMAL A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1):12-49.
[2] VOGEL A, MEYER T, SAPISOCHIN G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360):1345-1362.
[3] EL-SERAG H B. Epidemiology of viral hepatitis and hepatocellular carcinoma[J]. Gastroenterology, 2012, 142(6):1264-1273.e1.
[4] KOKUDO N, TAKEMURA N, HASEGAWA K, et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update[J]. Hepatol Res, 2019, 49(10):1109-1113.
[5] TOMASI T B JR. Structure and function of alpha-fetoprotein[J]. Annu Rev Med, 1977, 28:453-465.
[6] FARINATI F, MARINO D, DE GIORGIO M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?[J]. Am J Gastroenterol, 2006, 101(3):524-532.
[7] SAITTA C, RAFFA G, ALIBRANDI A, et al. PIVKA-Ⅱ is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients[J]. Medicine (Baltimore), 2017, 96(26):e7266.
[8] SCHIEVING J H, DE VRIES M, VAN VUGT J M, et al. Alpha-fetoprotein, a fascinating protein and biomarker in neurology[J]. Eur J Paediatr Neurol, 2014, 18(3):243-248.
[9] LIEBMAN H A, FURIE B C, TONG M J, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma[J]. N Engl J Med, 1984, 310(22):1427-1431.
[10] FENG H, LI B, LI Z, et al. PIVKA-Ⅱ serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer. 2021; 21(1):401.
[11] LI C, ZHANG Z, ZHANG P, et al. Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: A systematic review[J]. Hepatol Res, 2014, 44(10):E11-E25.
[12] YU R, TAN Z, XIANG X, et al. Effectiveness of PIVKA-Ⅱ in the detection of hepatocellular carcinoma based on real-world clinical data[J]. BMC Cancer, 2017, 17(1):608.
[13] KIM D Y, PAIK Y H, AHN S H, et al. PIVKA-Ⅱ is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection[J]. Oncology, 2007, 72 Suppl 1:52-57.
[14] KAIBORI M, MATSUI Y, YANAGIDA H, et al. Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma[J]. World J Surg, 2004, 28(7):702-707.
[15] CONCHIE J, HAY A J. Mammalian glycosidases. 4. The intracellular localization of beta-galactosidase, alpha-mannosidase, beta-N-acetylglucosaminidase and alpha-L-fucosidase in mammalian tissues[J]. Biochem J, 1963, 87(2):354-361.
[16] XING H, QIU H, DING X, et al. Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma[J]. Biomark Med, 2019, 13(7):545-555.
[17] WANG K, GUO W, LI N, et al. Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma followi-ng hepatectomy: a large-scale, long-term study[J]. Br J Cancer, 2014, 110(7):1811-1819.
[18] YANG Z F, HO D W, NG M N, et al. Significance of CD90+ cancer stem cells in human liver cancer[J]. Cancer Cell, 2008, 13(2):153-166.
[19] LIU S, LI N, YU X, et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells[J]. Gastroenterology, 2013, 144(5):1031-1041.e10.
[20] WANG S, ZHANG C, WANG G, et al. Aptamer-mediated transparent-biocompatible nanostructured surfaces for hepotocellular circulating tumor cells enrichment[J]. Theranostics, 2016, 6(11):1877-1886.
[21] QI L N, XIANG B D, WU F X, et al. Circulating tumor cells undergoing emt provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma[J]. Cancer Res, 2018, 78(16):4731-4744.
[22] SUN Y F, WU L, LIU S P, et al. Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma[J]. Nat Commun, 2021, 12(1):4091.
[23] SAUSEN M, PARPART S, DIAZ L A JR. Circulating tumor DNA moves further into the spotlight[J]. Genome Med, 2014, 6(5):35.
[24] VAN DER POL Y, MOULIERE F. Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA[J]. Cancer Cell, 2019, 36(4):350-368.
[25] CHEN L, ABOU-ALFA G K, ZHENG B, et al. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients[J]. Cell Res, 2021, 31(5):589-592.
[26] DING Y, YAO J, WEN M, et al. The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma[J]. PeerJ, 2022, 10:e13473.
[27] XU R H, WEI W, KRAWCZYK M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater, 2017, 16(11):1155-1161.
[28] ZHANG B O, XU C W, SHAO Y, et al. Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation[J]. Exp Ther Med, 2015, 9(4):1383-1388.
[29] HA M, KIM V N. Regulation of microRNA biogenesis[J]. Nat Rev Mol Cell Biol, 2014, 15(8):509-524.
[30] LU J, GETZ G, MISKA E A, et al. MicroRNA expression profiles classify human cancers[J]. Nature, 2005, 435(7043):834-838.
[31] CHEN X, BA Y, MA L, et al. Characterization of micro-RNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases[J]. Cell Res, 2008, 18(10):997-1006.
[32] FORNARI F, GRAMANTIERI L, GIOVANNINI C, et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells[J]. Cancer Res, 2009, 69(14):5761-5767.
[33] COULOUARN C, FACTOR V M, ANDERSEN J B, et al. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties[J]. Oncogene, 2009, 28(40):3526-3536.
[34] ASHMAWY A M, ELGESHY K M, ABDEL SALAM E T, et al. Crosstalk between liver-related microRNAs and Wnt/β-catenin pathway in hepatocellular carcinoma patients[J]. Arab J Gastroenterol, 2017, 18(3):144-150.
[35] ZHOU S J, LIU F Y, ZHANG A H, et al. MicroRNA-199b-5p attenuates TGF-β1-induced epithelial-mesenchymal transition in hepatocellular carcinoma[J]. Br J Cancer, 2017, 117(2):233-244.
[36] YAN X L, JIA Y L, CHEN L, et al. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: role of the S100A4-miR155-SOCS1-MMP9 axis[J]. Hepatology, 2013, 57(6):2274-2286.
[37] MORISHITA A, OURA K, TADOKORO T, et al. Micro-RNAs in the pathogenesis of hepatocellular carcinoma: a review[J]. Cancers (Basel), 2021, 13(3):514.
[38] CALLEGARI E, GRAMANTIERI L, DOMENICALI M, et al. MicroRNAs in liver cancer: a model for investiga-ting pathogenesis and novel therapeutic approaches[J]. Cell Death Differ, 2015, 22(1):46-57.
[39] ZHANG T, YANG Z, KUSUMANCHI P, et al. Critical role of microRNA-21 in the pathogenesis of liver diseases[J]. Front Med (Lausanne), 2020, 7:7.
[40] WANG C, WANG X, SU Z, et al. MiR-25 promotes hepatocellular carcinoma cell growth, migration and invasion by inhibiting RhoGDI[J]. Oncotarget, 2015, 6(34):36231-36244.
[41] TANG H, LI R P, LIANG P, et al. miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway[J]. Oncol Lett, 2015, 10(2):681-686.
[42] COPPOLA N, DE STEFANO G, PANELLA M, et al. Lowered expression of microRNA-125a-5p in human hepatocellular carcinoma and up-regulation of its oncogenic targets sirtuin-7, matrix metalloproteinase-11, and c-Raf[J]. Oncotarget, 2017, 8(15):25289-25299.
[43] BI Q, TANG S, XIA L, et al. Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF[J]. PLoS One, 2012, 7(6):e40169.
[44] CHANG R M, XIAO S, LEI X, et al. miRNA-487a promotes proliferation and metastasis in hepatocellular carcinoma[J]. Clin Cancer Res, 2017, 23(10):2593-2604.
[45] BAO L, ZHANG M, HAN S, et al. MicroRNA-500a promotes the progression of hepatocellular carcinoma by post-transcriptionally targeting BID[J]. Cell Physiol Biochem, 2018, 47(5):2046-2055.
[46] GUO Y, CHEN L, SUN C, et al. MicroRNA-500a promotes migration and invasion in hepatocellular carcinoma by activating the Wnt/β-catenin signaling pathway[J]. Biomed Pharmacother, 2017, 91:13-20.
[47] ZHANG Y, ZHANG D, JIANG J, et al. Loss of miR-638 promotes invasion and epithelial-mesenchymal transition by targeting SOX2 in hepatocellular carcinoma[J]. Oncol Rep, 2017, 37(1):323-332.
[48] DING D, ZHANG Y, YANG R, et al. miR-940 suppresses tumor cell invasion and migration via regulation of CXCR2 in hepatocellular carcinoma[J]. Biomed Res Int, 2016, 2016:7618342.
[49] LIU A M, YAO T J, WANG W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study[J]. BMJ Open, 2012, 2(2):e000825.
[50] AMR K S, ELMAWGOUD ATIA H A, ELAZEEM ELBNHAWY R A, et al. Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma[J]. Genes Dis, 2017, 4(4):215-221.
[51] XU J, WU C, CHE X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis[J]. Mol Carcinog, 2011, 50(2):136-142.
[52] KALLURI R, LEBLEU V S. The biology, function, and biomedical applications of exosomes[J]. Science, 2020, 367(6478):eaau6977.
[53] NABET B Y, QIU Y, SHABASON J E, et al. Exosome RNA unshielding couples stromal activation to pattern recognition receptor signaling in cancer[J]. Cell, 2017, 170(2):352-366.e13.
[54] THéRY C. Cancer: Diagnosis by extracellular vesicles[J]. Nature, 2015, 523(7559):161-162.
[55] LU Y, DUAN Y, XU Q, et al. Circulating exosome-derived bona fide long non-coding RNAs predicting the occurrence and metastasis of hepatocellular carcinoma[J]. J Cell Mol Med, 2020, 24(2):1311-1318.
[56] CONIGLIARO A, COSTA V, LO DICO A, et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA[J]. Mol Cancer, 2015, 14:155.
[57] SUN N, LEE Y T, ZHANG R Y, et al. Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring[J]. Nat Commun, 2020, 11(1):4489.
[58] LLOVET J M, KELLEY R K, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):6.
[59] SCHULZE K, IMBEAUD S, LETOUZé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets[J]. Nat Genet, 2015, 47(5):505-511.
[60] GUICHARD C, AMADDEO G, IMBEAUD S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma[J]. Nat Genet, 2012, 44(6):694-698.
[61] LIU X, XIAO C, YUE K, et al. Identification of multi-o-mics biomarkers and construction of the novel prognostic model for hepatocellular carcinoma[J]. Sci Rep, 2022, 12(1):12084.
Outlines

/